14 June 2019 - - Switzerland-based biopharmaceutical group Debiopharm and France-based biopharmaceutical group Ipsen have renewed their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets, the company said.
Having established their collaboration in the 1980s, this extension represents a long-term commitment to patients, offering the benefits of Decapeptyl in the treatment of metastatic and non-metastatic patients with locally advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty and endocrine-responsive early-stage breast cancer.
Under the renewed agreement, both parties will co-develop novel formulations and explore additional indications for other patient populations with high unmet needs.
Decapeptyl (triptorelin pamoate) is an agonist analogue of the natural gonadotropin-releasing hormone, currently available in three sustained-release formulations (1, 3 and 6 months).
First registered in France in 1986, triptorelin is currently marketed in more than 80 countries, being the market leader in many territories worldwide.
The alliance between Debiopharm and Ipsen for Decapeptyl has successfully delivered sustained market growth with EUR 372.6m total sales in 2018, representing 8.1% annual growth.
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, the company identifies high-potential compounds for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialisation partners to maximise patient access globally.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases.
Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business.
With total sales over EUR 2.2bn in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries.
Ipsen's R and D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The group has about 5,700 employees worldwide.
Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt programme (ADR: IPSEY).